Related Experiment Videos
Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic
S Rosthøj1, S Nielsen, F K Pedersen
1Department of Paediatrics, Aalborg Hospital, Denmark.
Insights
Intravenous immunoglobulin (IVIG) is more effective than intravenous methylprednisolone pulse therapy (MPPT) for treating children with newly diagnosed idiopathic thrombocytopenic purpura (ITP). IVIG rapidly increases platelet counts and is often sufficient as initial therapy.
Area of Science:
- Pediatric Hematology
- Immunology
- Clinical Trials
Background:
- Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by low platelet counts.
- Effective initial treatment is crucial for managing ITP in children, particularly those with severe bleeding or lack of spontaneous platelet recovery.
Purpose of the Study:
- To compare the efficacy of intravenous immunoglobulin (IVIG) versus intravenous methylprednisolone pulse therapy (MPPT) as first-line treatments for pediatric ITP.
- To evaluate platelet response, achievement of hemostatic levels, and long-term outcomes in children with ITP.
Main Methods:
- A randomized controlled trial involving 43 children with newly diagnosed ITP.
- Participants received either IVIG (1 g/kg) or MPPT (30 mg/kg) on two consecutive days.
- Platelet counts were monitored, and cross-over treatment was administered for non-responders.
Main Results:
- IVIG induced significantly greater and faster platelet count increases compared to MPPT within 72 hours (188 vs. 77 x 10^9/L).
- IVIG achieved hemostatically safe platelet levels (>50 x 10^9/L) more frequently (91% vs. 50%).
- While initial responses favored IVIG, long-term normal platelet counts and relapse rates were not significantly different between groups after 6 months.
Conclusions:
- IVIG demonstrates superior initial efficacy in rapidly increasing platelet counts in children with ITP compared to MPPT.
- IVIG may be a preferable initial treatment option due to its rapid and effective platelet response.
- Further investigation into long-term outcomes and optimal treatment strategies for pediatric ITP is warranted.
Abstract:
Forty-three children with newly diagnosed idiopathic thrombocytopenic purpura (ITP), platelet count (PC) below 20 x 10(9)l-1, and either continued bleeding or failure to show a spontaneous rise in the PC after a 3 day observation period were randomized to treatment with either intravenous immunoglobulin (IVIG) infusions 1 g kg-1 (n = 23) or intravenous methylprednisolone pulse therapy (MPPT) 30 mg kg-1 (n = 20) on two consecutive days. After 72 h, IVIG had induced greater platelet responses (mean PC 188 x 10(9) versus 77 x 10(9)l-1, 2p < 0.001) and raised the PC to a haemostatically safe level above 50 x 10(9)l-1 more frequently (91 versus 50%, one-sided exact p = 0.003). Children responding poorly were then given the alternative treatment in addition. After 6 days, a normal PC of over 150 x 10(9)l-1 had been obtained more frequently in the group given first-line IVIG (70 versus 50%, p = 0.16). The relapse rates during 6 months of follow-up were not significantly different (26 versus 40%, p = 0.26). Cross-over treatment in 11 children with relapse confirmed the superior response to IVIG. The treatment given was restricted to the two initial infusions more often in the IVIG group (70 versus 35%, p = 0.05). These results indicate that IVIG may be preferable to MPPT as the initial treatment for ITP.